Home

CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome, vaccines, and devices.

107+

$million

Invested

30+

company

Projects

6

different

Countries

12

new antibiotic classes in

Pipeline

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address the emergence of drug-resistant superbugs.
Learn More


Spotlight on Science

SciBac is fighting fire with fire by using improved bugs as drugs

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Drug Resistant Infections, Wellcome Trust
Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.

Funders

ASPR
BARDA
WellcomeTrust
NIAID
UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators

Boston University
RTI
CLSI
MassBio
Broad Institute
DTRA
Wellcome Trust

Events

Events

02.21.19

,

Webinar - NIAID Resources to Facilitate Discovery & Development of Anti-Infectives

03.06.19

Chausa, India

US FDA Regulatory Approval Process for Anti-microbials Workshhop

03.14.19

Berlin, Germany

The 12th Berlin Conference on Life Sciences - Novel Antimicrobials and AMR Diagnostics 2019

CARB-X News

  • 02.06.2019  |  CARB-X funds Recida Therapeutics to develop a new class of antibiotics to treat deadly infections caused by Gram-negative superbugs full release

  • 02.04.2019  |  CARB-X funds Polyphor to develop a new class of antibiotics to treat serious infections caused by Gram-negative ESKAPE superbugs full release

  • 01.03.2019  |  CARB-X backs Forge to develop a new class of antibiotics to treat serious lung infections caused by Gram-negative bacteria, including multi-drug resistant P. aeruginosa full release

See All News

In The News

  • 02.18.2019  |  Free Resource Against Infections – Novartis contributes to PEW’s SPARK open-science database full story

  • 02.18.2019  |  Viral, bacterial diagnostics bolster antimicrobial stewardship full story

  • 02.12.2019  |  Antimicrobial resistance: The Ten Commandments – Two Years On – A Response full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.